Hemophilia Archives

Latest Posts

News and Trends 2 Nov 2017

Close to Launching Gene Therapy, Dutch Biotech Raises Over $91M on the Nasdaq

Update (2/11/2017): uniQure has closed its public offering raising over $91m (€78M) on the Nasdaq, taking advantage of a massive stock jump triggered by the announcement that an improved version of its…

November 2, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Oct 2017

Dutch Biotech plans Pivotal Clinical Trial with First Gene Therapy for Hemophilia

uniQure is getting ready to start a Phase III clinical trial in 2018 with a new version of its gene therapy for hemophilia B. uniQure has officially launched a plan…

October 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Bicycle Therapeutics Bioverativ Hemophilia blood disorders

News and Trends 6 Sep 2017

A €344M Partnership will Develop Bicycle Drugs for Hemophilia

Bicycle Therapeutics has partnered with Bioverativ to develop a new class of drugs for patients with rare blood disorders like hemophilia and sickle cell disease. Bicycle Therapeutics, a money-magnet biotech…

September 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

novimmune shire hemophilia antibody roche

News and Trends 18 Jul 2017

Shire In-Licenses Swiss Antibody for Hemophilia A to Compete with Roche

Shire has bought exclusive worldwide rights to develop and commercialize a bispecific antibody from Novimmune that could improve the treatment of hemophilia A. Novimmune is a biotech from Geneva that…

July 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 10 Jul 2017

Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi

Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi drug fitusiran in the competitive hemophilia market. Sanofi and its partner Alnylam have announced the…

July 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Trevor Baglin XO1 SuperX Virtual Biotech

Interview 19 Jun 2017

Discussing the Virtual Biotech Model with XO1 Co-Founder Trevor Baglin

Academic, entrepreneur and now venture partner Trevor Baglin discusses his successful experience working with the unique model of virtual biotech. Trevor Baglin, along with Jim Huntington and David Grainger,…

June 19, 2017 - 7 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Apr 2017

EMA designates uniQure’s gene therapy for hemophilia a priority

Following a Breakthrough Designation from the FDA earlier this year, the Dutch biotech has scored the European equivalent for AMT-060. Since its claim to fame, Glybera, fell from grace to become a commercial…

April 25, 2017 - 3 minutesmins - By Evelyn Warner

News and Trends 28 Feb 2017

It’s Global Rare Disease Day! What Cures is Biotech Cooking Up?

We've compiled a list of some of the latest advances of biotech in the field of rare disease to contribute to Rare Disease Day 2017. The European Organization for…

February 28, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jan 2017

The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy

UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy for hemophilia B. UniQure is one of the companies leading the development of gene therapy…

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 9 Jan 2017

After a Rough Year, uniQure CMO discusses a Comeback

Last year was a bad year for biotech as an industry, but it was particularly bad for uniQure. Here's what its CMO has to say about the company's recovery. After…

January 9, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 20 Dec 2016

UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data

UniQure's gene therapy for Hemophilia B is performing well in clinical trials, but the company faces many challenges with its current financial situation. Can it manage to make it to the…

December 20, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

liver anatomy organs Sebastian Kaulitzki fi

News and Trends 21 Nov 2016

“We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease”

Promethera is collecting cash to fuel its liver disease program that revolves around HepaStem. I sat down with the CEO to hear more about the link between the company's seemingly…

November 21, 2016 - 7 minutesmins - By Evelyn Warner

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with world-leading academics working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering